表紙
市場調査レポート

Quantum Pharmaceuticals : 製品パイプライン分析

Quantum Pharmaceuticals - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 305186
出版日 ページ情報 英文 20 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.95円で換算しております。
Back to Top
Quantum Pharmaceuticals : 製品パイプライン分析 Quantum Pharmaceuticals - Product Pipeline Review - 2015
出版日: 2015年08月31日 ページ情報: 英文 20 Pages
概要

Quantum Pharmaceuticals は、計算創薬プラットフォーム (QUANTUM)を開発し、創薬サービスを提供しています。同社の製品にはHIV阻害薬や癌の代謝阻害剤、および抗生剤があります。

当レポートでは、Quantum Pharmaceuticalsにおける治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Quantum Pharmaceuticalsの基本情報

  • Quantum Pharmaceuticalsの概要
  • 主要情報
  • 企業情報

Quantum Pharmaceuticals:R&Dの概要

  • 主な治療範囲

Quantum Pharmaceuticals:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

Quantum Pharmaceuticals:パイプライン製品の概況

  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ

Quantum Pharmaceuticals:薬剤プロファイル

  • Small Molecule to Inhibit MA p17 for HIV Infections
  • Small Molecules for Neuroprotection
  • Small Molecules to Inhibit PFKFB3 for Neurodegenerative Diseases and Cancer
  • Small Molecules to Inhibit Shc-Transforming Protein 1 for Type 2 Diabetes

Quantum Pharmaceuticals:パイプライン分析

  • 標的別
  • 分子タイプ別
  • 作用機序別

Quantum Pharmaceuticals:休止中のプロジェクト

Quantum Pharmaceuticals:本社と子会社の所在地

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07387CDB

Summary

Global Markets Direct's, 'Quantum Pharmaceuticals - Product Pipeline Review - 2015', provides an overview of the Quantum Pharmaceuticals's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Quantum Pharmaceuticals's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Quantum Pharmaceuticals including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Quantum Pharmaceuticals's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Quantum Pharmaceuticals's pipeline products

Reasons to buy

  • Evaluate Quantum Pharmaceuticals's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Quantum Pharmaceuticals in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Quantum Pharmaceuticals's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Quantum Pharmaceuticals and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Quantum Pharmaceuticals
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Quantum Pharmaceuticals and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Quantum Pharmaceuticals Snapshot
    • Quantum Pharmaceuticals Overview
    • Key Information
    • Key Facts
  • Quantum Pharmaceuticals - Research and Development Overview
    • Key Therapeutic Areas
  • Quantum Pharmaceuticals - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Quantum Pharmaceuticals - Pipeline Products Glance
    • Quantum Pharmaceuticals - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Quantum Pharmaceuticals - Drug Profiles
    • Small Molecule to Inhibit MA p17 for HIV Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Neuroprotection
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit PFKFB3 for Neurodegenerative Diseases and Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Shc-Transforming Protein 1 for Type 2 Diabetes
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Quantum Pharmaceuticals - Pipeline Analysis
  • Quantum Pharmaceuticals - Pipeline Products by Target
  • Quantum Pharmaceuticals - Pipeline Products by Molecule Type
  • Quantum Pharmaceuticals - Pipeline Products by Mechanism of Action
  • Quantum Pharmaceuticals - Dormant Projects
  • Quantum Pharmaceuticals - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Quantum Pharmaceuticals, Key Information
  • Quantum Pharmaceuticals, Key Facts
  • Quantum Pharmaceuticals - Pipeline by Indication, 2015
  • Quantum Pharmaceuticals - Pipeline by Stage of Development, 2015
  • Quantum Pharmaceuticals - Monotherapy Products in Pipeline, 2015
  • Quantum Pharmaceuticals - Preclinical, 2015
  • Quantum Pharmaceuticals - Pipeline by Target, 2015
  • Quantum Pharmaceuticals - Pipeline by Molecule Type, 2015
  • Quantum Pharmaceuticals - Pipeline Products by Mechanism of Action, 2015
  • Quantum Pharmaceuticals - Dormant Developmental Projects,2015

List of Figures

  • Quantum Pharmaceuticals - Pipeline by Top 10 Indication, 2015
  • Quantum Pharmaceuticals - Pipeline by Top 10 Target, 2015
  • Quantum Pharmaceuticals - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top